Premium
Anakinra for Colchicine‐Resistant Familial Mediterranean Fever: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Author(s) -
BenZvi Ilan,
Kukuy Olga,
Giat Eitan,
Pras Elon,
Feld Olga,
Kivity Shaye,
Perski Oleg,
Bornstein Gil,
Grossman Chagai,
Harari Gil,
Lidar Merav,
Livneh Avi
Publication year - 2017
Publication title -
arthritis and rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.106
H-Index - 314
eISSN - 2326-5205
pISSN - 2326-5191
DOI - 10.1002/art.39995
Subject(s) - anakinra , medicine , familial mediterranean fever , placebo , colchicine , adverse effect , placebo controlled study , randomized controlled trial , surgery , double blind , pathology , alternative medicine , disease
Objective Familial Mediterranean fever (FMF) is refractory to colchicine prophylaxis in 10–20% of patients. In a number of patient series, treatment with anakinra, an interleukin‐1–blocking agent, prevented FMF attacks in those with colchicine‐resistant FMF. This study was undertaken to evaluate the efficacy and safety of anakinra in the treatment of colchicine‐resistant FMF, using a randomized controlled trial. Methods Patients with colchicine‐resistant FMF receiving colchicine (dosage ≥1.5 to ≤3 mg/day) were recruited and randomly assigned to receive anakinra or placebo (vehicle). The treatment duration was 4 months. Primary efficacy outcomes were the number of attacks per month, and the number of patients with a mean of <1 attack per month. Quality of life was assessed using a 0–10‐grade visual analog scale (VAS), and safety was assessed according to the number and severity of adverse events. Results Twenty‐five patients with colchicine‐resistant FMF (14 women) were enrolled, of whom 12 were randomized to receive anakinra and 13 to receive placebo. The mean ± SD number of attacks per patient per month was 1.7 ± 1.7 in those receiving anakinra and 3.5 ± 1.9 in those receiving placebo ( P = 0.037). Six patients in the anakinra group, compared to none in the placebo group, had <1 attack per month ( P = 0.005). A beneficial effect of anakinra was noted in the number of attacks in the joints per month in patients receiving anakinra (mean ± SD 0.8 ± 1.6 versus 2.1 ± 1.1 in the placebo group; P = 0.019) and in quality of life (mean ± SD VAS score 7.7 ± 2.3 in the anakinra group versus 4.2 ± 2.9 in the placebo group; P = 0.045). The number of adverse events per patient per month was comparable between the anakinra group and the placebo group (mean ± SD 2.03 ± 1.75 versus 3.34 ± 2.5; P = 0.22). There were no severe adverse events. Conclusion In this randomized controlled trial, anakinra appears to be an effective and safe treatment for colchicine‐resistant FMF.